natgillin/translations-raw huggingface dataset:
preparing antibodies or antibody fragments from said immunized animal, wherein said antibodies bind said KIR polypeptide, 
priprema protutijela ili fragmenata protutijela iz imunizirane životinje, gdje se ta protutijela vežu za KIR polipetid,
selecting antibodies or antibody fragments of (b) that cross-react with at least KIR2DL1, KIR2DL2 and KIR2DL3, and 
odabir protutijela ili fragmenata protutijela iz (b) koji križno reagiraju barem s KIR2DL1, KIR2DL2 i KIR2DL3, i
selecting antibodies or antibody fragments of (c) that capable of neutralizing KIR-mediated inhibition of NK cell cytotoxicity on a population of NK cells expressing said at least two different human inhibitory KIR receptor gene products, wherein the order of steps (c) and (d) is optionally reversed and wherein the antibody or antibody fragment binds KIR2DL1, KIR2DL2 and KIR2DL3 and wherein KIR2DL2 and KIR2DL3 are considered to be a single inhibitory KIR molecule. 
odabir protutijela ili fragmenata protutijela iz (c) koji mogu neutralizirati KIR-om posredovanu inhibiciju citotoksičnosti NK stanica na populaciji NK stanica koje eksprimiraju ta barem dva različita genska produkta humanog inhibitornog KIR receptora, gdje se redoslijed koraka (c) i (d) po izboru može zamijeniti i gdje protutijelo ili fragment protutijela veže KIR2DL1, KIR2DL2 i KIR2DL3 i gdje KIR2DL2 i KIR2DL3 smatraju se jednom inhibitornom KIR molekulom.
The method of claim 15, wherein the inhibitory KIR polypeptide used for immunization is a KIR2DL polypeptide and the antibodies selected in step (c) cross-react with at least KIR2DL1 and KIR2DL2/3. 
Postupak prema zahtjevu 15, gdje je inhibitorni KIR polipetid, koji se koristi za imunizaciju, KIR2DL polipeptid i protutijela izabrana u koraku (c) križno reagiraju barem s KIR2DL1 i KIR2DL2/3.
The method of claim 17, wherein said antibodies or antibody fragments selected in step (c) inhibits the binding of a HLA-c allele molecule having a Lys residue at position 80 to a human KIR2DL1 receptor, and the binding of a HLA-C allele molecule having an Asn residue at position 80 to human KIR2DL2/3 receptors. 
Postupak prema zahtjevu 17, gdje to protutijelo ili fragmenti protutijela izabranog u koraku (c) inhibira vezanje HLA-c alel molekule koja ima Lys ostatak na položaju 80, za humani KIR2DL1 receptor, i vezanje HLA-C alel molekule, koja ima Asn ostatak na položaju 80, za humane KIR2DL2/3 receptore.
The method of claim 15, wherein the antibodies or antibody fragments selected in step (d), cause at least 50% of the lysis of target cells observed with NK cells or NK cell lines that are not blocked by their KIR, as measured by a chromium release test of cytotoxicity, in an NK cell population expressing a given KIR in contact with target cells expressing the cognate MHC class I molecule. 
Postupak prema zahtjevu 15, gdje to protutijelo ili fragmenti protutijela izabrani u koraku (d), uzrokuju barem 50% lize ciljnih stanica zabilježene s NK stanicama ili linijama NK stanica koje nisu blokirane svojim KIR-om, mjereno testom citotoksičnosti oslobađanjem kroma, u populaciji NK stanica koje eksprimiraju dani KIR u kontaktu s ciljnim stanicama koje eksprimiraju srodnu molekulu MHC klase I.
selecting, from a library or repertoire, a monoclonal antibody or an antibody fragment that cross-reacts with at least two different human inhibitory KIR2DL receptor gene products, and 
odabir, iz knjižnice ili repertoara, monoklonskog protutijela ili fragmenta protutijela koje križno reagira s barem dva različita genska produkta humanog inhibitornog KIR2DL, i
The method of claim 22, wherein the antibody selected in step (b) inhibits the binding of a HLA-c allele molecule having a Lys residue at position 80 to a human KIR2DL1 receptor, and the binding of a HLA-C allele molecule having an Asn residue at position 80 to human KIR2DL2/3 receptors. 
Postupak prema zahtjevu 22, gdje protutijelo izabrano u koraku (b) inhibira vezanje HLA-c alel molekule koja ima Lys ostatak na položaju 80, za humani KIR2DL1 receptor, i vezanje HLA-C alel molekule, koja ima Asn ostatak na položaju 80, za humane KIR2DL2/3 receptore.
The method of claim 22, wherein the antibody selected in step (b), causes at least 50% of the lysis of target cells observed with NK cells or NK cell lines that are not blocked by their KIR, as measured by a chromium release test of cytotoxicity, in an NK cell population expressing a given KIR in contact with target cells expressing the cognate MHC class I molecule. 
Postupak prema zahtjevu 22, gdje protutijelo izabrano u koraku (b), uzrokuju barem 50% lize ciljnih stanica zabilježene s NK stanicama ili linijama NK stanica koje nisu blokirane svojim KIR-om, mjereno testom citotoksičnosti oslobađanjem kroma, u populaciji NK stanica koje eksprimiraju dani KIR u kontaktu s ciljnim stanicama koje eksprimiraju srodnu molekulu MHC klase I.
separating said monoclonal antibody from said hybridoma. 
odvajanje tog monoklonskog protutijela od hibridoma.
inserting said DNA or modified DNA into an expression vector, wherein said antibody or antibody fragment is capable of being expressed when said expression vector is present in a host grown under appropriate conditions; 
umetanje DNA ili modificirane DNA u vektor ekspresije, gdje to protutijelo ili fragment protutijela može biti eksprimirano kada je taj vektor ekspresije prisutan u domaćinu koji se uzgaja u odgovarajućim uvjetima;
culturing said transfected host cell under conditions which cause the expression of said antibody or antibody fragment; and 
uzgoj kulture transfecirane stanice domaćina u uvjetima koji uzrokuju ekspresiju tog protutijela ili fragmenta protutijela; i
isolating the antibody or antibody fragment produced by said transfected host cell. 
izolacija protutijela ili fragmenta protutijela koje je proizvela ta transfecirana stanice domaćin.
The composition of claim 31, further comprising a therapeutic agent selected from an immunomodulatory agent, a hormonal agent, a chemotherapeutic agent, an anti-angiogenic agent, an apoptotic agent, a second antibody that binds to and inhibits an inhibitory KIR receptor, an anti -infective agent, a targeting agent or an adjunct compound. 
Oblik prema zahtjevu 31, koji dalje sadrži terapijsko sredstvo izabrano između imunomodulatornog sredstva, hormona, kemoterapijskog sredstva, anti-angiogeničnog sredstva, apoptotičnog sredstva, drugog protutijela koje veže i inhibira taj inhibitorni KIR receptor, anti-infektivnog sredstva, ciljnog sredstva ili dodatnog spoja.
The composition of claim 33 or 34, wherein said chemotherapeutic agent is selected from alkylating agents, antimetabolites, cytotoxic antibiotics, adriamycin, dactinomycin, mitomycin, carminomycin, daunomycin, doxorubicin, tamoxifen, taxol, taxotere, vincristine, vinblastine, vinorelbine, etoposide (VP-16), 5-fluorouracil (5FU), cytosine arabinoside, cyclophosphamide, thiotepa, methotrexate, camptothecin, actinomycin-D, mitomycin C, cisplatin (CDDP), aminopterin, combretastatin(s), other vinca alkyloids, and derivatives or prodrugs thereof. 
Oblik prema zahtjevu 33 ili 34, gdje se to kemoterapijsko sredstvo izabire između alkilirajućih sredstava, antimetabolita, citotoksičnih antibiotika, adriamicina, daktinomicina, mitomicina, karminomicina, daunomicina, doksorubicina, tamoksifena, taksola, taksoter, vinkristina, vinblastina, vinorelbina, etopozida (VP-16), 5-fluorouracila (5FU), citozin arabinozida, ciklofosfamida, tiotepa, metotreksata, kamptotecina, aktinomicina-D, mitomicina C, cisplatina (CDDP), aminopterina, kombretastatina, drugih vinka alkaloida, i njihovih derivata ili pro-lijekova.
The composition of claim 33 or 34, wherein said hormonal agent is selected from leuprorelin, goserelin, triptorelin, buserelin, tamoxifen, toremifene, flutamide, nilutamide, cyproterone bicalutamid anastrozole, exemestane, letrozole, fadrozole medroxy, chlormadinone, megestrol, other LHRH agonists, other anti-estrogens, other anti-androgens, other aromatase inhibitors, and other progestagens. 
Oblik prema zahtjevu 33 ili 34, gdje se taj hormon izabire između leuprorelina, goserelina, triptorelina, buserelina, tamoksifena, toremifena, flutamida, nilutamida, ciproterona, bikalutamida, anastrozola, eksemestana, letrozola, fadrozola, medroksi, klormadinona, megestrola, drugih LHRH agonista, drugih anti-estrogena, drugih anti-androgena, drugih inhibitora aromataze i drugih progestagena.
The composition of claim 33 or 34, wherein said adjunct compound is selected from phenothiazines, substituted benzamides, antihistamines, butyrophenones, corticosteroids, benzodiazepines, cannabinoids, zoledronic acid, pamidronic acid, erythropoietin, G-CSF, filgrastim, lenograstim, darbepoietin other anti-emetics, other serotonin antagonists, other bisphosphonatesor other hematopoietic growth factors. 
Oblik prema zahtjevu 33 ili 34, gdje se dodatni spoj izabire između fenotiazina, supstituiranih benzamida, antihistamina, butirofenona, kortikosteroida, benzodiazepina, kanabinoida, zoledronične kiseline, pamidronične kiseline, eritropoetina, G-CSF, filgrastima, lenograstima, darbepoetina, drugih anti-emetika, drugih antagonista serotonina, drugih bisfosfonata ili drugih hematopoetskih faktora rasta.
The composition of claim 33 or 34, wherein said anti-angiogenic agent is selected from neutralizing antibodies, antisense RNA, siRNA, RNAi, RNA aptamers or ribozymes directed against a gene encoding VEGF, a gene encoding a VEGF receptors, VEGF, or a VEGF receptor; or a variant of VEGF possessing antagonistic properties against VEGF. 
Oblik prema zahtjevu 33 ili 34, gdje se anti-angiogenično sredstvo izabire između neutralizirajućih protutijela, nekodirajuće RNA, siRNA, RNAi, RNA aptamera ili ribozima usmjerenih protiv gena koji kodira VEGF, gena koji kodira VEGF receptore, VEGF, ili VEGF receptor; ili varijante VEGF koja ima antagonistička svojstva protiv VEGF.
Composition of claim 42, wherein said patient is suffering from cancer, another proliferative disorder, an infectious disease or an immune disorder. 
Oblik prema zahtjevu 42, gdje taj bolesnik boluje od raka, drugog proliferativnog poremećaja, infektivne bolesti ili imunog poremećaja.
Composition of claim 43, wherein said patient is suffering from squamous cell carcinoma, leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma, Burketts lymphoma, acute or chronic myelogenous leukemias, promyelocytic leukemia, fibrosarcoma, rhabdomyoscarcoma; melanoma, seminoma, teratocarcinoma, neuroblastoma, glioma, astrocytoma, neuroblastoma, glioma, schwannomas; fibrosarcoma, rhabdomyoscaroma, osteosarcoma, melanoma, xeroderma pigmentosum, keratoacanthoma, seminoma, thyroid follicular cancer, teratocarcinoma, other carcinoma of the bladder, breast, colon, kidney, liver, lung, ovary, prostate, pancreas, stomach, cervix, thyroid or skin, other hematopoietic tumors of lymphoid lineage, other hematopoietic tumors of myeloid lineage, other tumors of mesenchymal origin, other tumors of the central or peripheral nervous system, or other tumors of mesenchymal origin. 
Oblik prema zahtjevu 43, gdje taj bolesnik boluje od karcinoma skvamoznih stanica, leukemije, akutne limfoticne leukemije, akutne limfoblastične leukemije, limfoma B-stanica, limfoma T-stanica, Hodgkinovog limfoma, ne-Hodgkinovog limfoma, limfoma dlakavih stanica, Burkettovog limfoma, akutnih ili kroničnih mijeloičnih leukemija, promijelocitne leukemije, fibrosarkoma, rabdomiosarkoma; melanoma, seminoma, teratokarcinoma, neuroblastoma, glioma, astrocitoma, schwannoma, osteosarkoma, kseroderme pigmentosum, keratoakantoma, raka folikula štitnjače, drugog karcinoma mjehura, dojke, kolona, bubrega, jetre, pluča, jajnika, prostate, gušterače, želuca, cerviksa, štitnjače ili kože, drugih hematopoetskih tumora limfoidne linije, drugih hematopoetskih tumira mijeloične linije, drugih tumora mezenhimskog porijekla, drugih tumora središnjeg ili perifernog živčanog sustava.
Composition of claim 43, wherein said patient is suffering from acute myeloblastic leukaemia (AML). 
Oblik prema zahtjevu 43, gdje taj bolesnik boluje od akutne mijeloblastične leukemije (AML).
Composition of claim 43, wherein said patient is suffering from non-Hodgkins lymphoma. 
Oblik prema zahtjevu 43, gdje taj bolesnik boluje od ne-Hodgkinovog limfoma.
Composition of claim 43, wherein said patient is suffering from a proliferative disorder selected from hyperplasias, fibrosis, angiogenesis, psoriasis, atherosclerosis, stenosis or restenosis following angioplasty, and other diseases characterized by smooth muscle proliferation in blood vessels. 
Oblik prema zahtjevu 43, gdje taj bolesnik boluje od proliferativnog poremećaja izabranog između hiperplazija, fibroze, angiogeneze, psorijaze, ateroskleroze, stenoze ili restenoze nakon angioplastike, i drugih bolesti naznačenih proliferacijom glatkih mišića u krvnim žilama.
Composition of claim 43, wherein said patient is suffering from an infectious disease caused by a virus selected from hepatitis type A, hepatitis type B, hepatitis type C, influenza, varicella, adenovirus, herpes simplex type I (HSV-1), herpes simplex type 2 (HSV-2), rinderpest, rhinovirus, echovirus, rotavirus, respiratory syncytial virus, papilloma virus, papilloma virus, cytomegalovirus, echinovirus, arbovirus, huntavirus, coxsackie virus, mumps virus, measles virus, rubella virus, polio virus or human immunodeficiency virus type I or type 2 (HIV-1, HIV-2). 
Oblik prema zahtjevu 43, gdje taj bolesnik boluje od infektivne bolesti uzrokovane virusom izabranim između hepatitia tipa A, hepatitisa tipa B, hepatitisa tipa C, influence, varicella, adenovirusa, herpesa simpleksa tipa I (HSV-1), herpesa simpleksa tipa 2 (HSV-2), rinderpesta, rinovirusa, echovirusa, rotavirusa, respiratornog sincicijskog virusa, papilloma virusa, citomegaloviruas, arbovirusa, huntavirusa, coxsackie virusa, virusa zaušnjaka, virusa ospica, rubella viruas, polio virusa ili virusa humane imunodeficijencije tipa tipa I ili tipa 2 (HIV-1, HIV-2).
Composition according to claim 43, comprising the medicament is used in combination with an appropriate additional therapeutic agent selected from an immunomodulatory agent, a hormonal agent, a chemotherapeutic agent, an anti-angiogenic agent, an apoptotic agent, a second antibody that binds to and inhibits an inhibitory KIR receptor, an anti -infective agent, a targeting agent or an adjunct compound wherein said additional therapeutic agent is administered to said patient as a single dosage form together with said antibody, or as separate dosage form. 
Oblik prema zahtjevu 43, sadrži lijek koji se koristi u kombinaciji s odgovarajućim dodatnim terapijskim sredstvom izabranim između imunomodulatornog sredstva, hormona, kemoterapijskog sredstva, anti-angiogeničnog sredstva, apoptotičnog sredstva, drugog protutijela koje veže i inhibira inhibitorni KIR receptor, anti-infektivnog sredstva, ciljnog sredstva ili dodatnog spoja gdje se to dodatno terapijsko sredstvo primjenjuje bolesniku kao jedan dozirni oblik zajedno s protutijelom, ili kao posebni dozirni oblik.
Composition according to claim 54, wherein said patient is suffering from a hematopoietic tumor of lymphoid lineage, acute myeloblastic leukaemia (AML) or non-Hodgkins lymphoma. 
Oblik prema zahtjevu 54, gdje taj bolesnik boluje od hematopoetskog tumora limfoidne linije, akutne mijeloblastične leukemije (AML) ili ne-Hodgkinovog limfoma.
Composition according to claim 54, wherein said patient is suffering from breast or ovarian carcinoma. 
Oblik prema zahtjevu 54, gdje taj bolesnik boluje od karcinoma dojke ili jajnika.
The antibody of claim 1, wherein said antibody or antibody fragment is conjugated or covalently bound to a toxin, a detectable moiety, or a solid support. 
Protutijelo prema zahtjevu 1, gdje je to protutijelo ili fragment protutijela konjugirano ili kovalento vezano za toksin, spoj koji se može detektirati ili čvrstu podlogu.
contacting said biological sample with an antibody or antibody fragment according to claim 57, wherein said antibody or antibody fragment is conjugated or covalently bound to a detectable moiety; and 
kontakt biološkog uzorka s protutijelom ili fragmentom protutijela prema zahtjevu 57, gdje je to protutijelo ili fragment protutijela konjugirano ili kovalento vezano za spoj koji se može detektirati; i
contacting said sample with an antibody or antibody fragment according to claim 57 under conditions that allow said NK cells bearing an inhibitory KIR on their cell surface to bind to said antibody or antibody fragment, wherein said antibody or antibody fragment is conjugated or covalently bound to a solid support; and 
kontakt uzorka s protutijelom ili fragmentom protutijela prema zahtjevu 57 u uvjetima koji omogućuju da se NK stanice, koje nose inhibitorni KIR na svojoj staničnoj površini, vežu za to protutijelo ili fragment protutijela, gdje je to protutijelo ili fragment protutijela konjugirano ili kovalento vezano za čvrstu podlogu; i
eluting said bound NK cells from said antibody or antibody fragment conjugated or covalently bound to a solid support. 
ispiranje tih vezanih NK stanica s protutijela ili fragmenta protutijela koje je konjugirano ili kovalento vezano za čvrstu podlogu.
A device as in any of the preceding claims wherein the polyurethane material of the coating (22) forms a cross-linked or linear matrix and the hydrophilic material is dispersed throughout the matrix. 
Uređaj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što poliuretanski materijal sloja za oblaganje (22) tvori umreženu matricu ili linearnu matricu, a hidrofilni materijal je raspoređen kroz cijelu matricu.
A device as in any of the preceding claims wherein the material of the internal surface (18) exhibits a flexural modulus that is at least 1200 MPa. 
Uređaj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što materijal unutarnje površine (18) ima modul savijanja, koji modul je najmanje 1200 MPa.
A device as in any of the preceding claims wherein the material of the internal surface (18) exhibits a hardness of at least 75D. 
Uređaj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što materijal unutarnje površine (18) ima tvrdoću od najmanje 75 D.
conjugating a maytansinoid to the antibodies having linkers bound thereto in the purified first mixture by reacting the antibodies having linkers bound thereto with a maytansinoid in a solution having a pH of 4 to 9 to prepare a second mixture comprising (i) antibody chemically coupled through the linker to the maytansinoid, (ii) free maytansinoid, and (iii) reaction by-products, and 
konjugacije maitanzinoida sa antitijelima koja imaju za sebe vezane linkere u pročišćenoj prvoj smjesi putem reakcije antitijela koja imaju za sebe vezane linkere sa maitanzinoidom u otopini koja ima pH od 4 do 9 da bi se pripremila druga smjesa koja sadrži (i) antitijelo kemijski spojeno preko linkera za maitanzinoid, (ii) slobodan maitanzinoid i (iii) sporedne proizvode reakcije, i
Medicament comprising at least one human Tr1 cell population directed against a human HSP. 
Lijek koji se u bitnome sastoji od najmanje jedne populacije ljudskih Tr1 stanica koji djeluje protiv ljudskog HSP-a (Heat shock proteina).
A medicament or a pharmaceutical composition according to anyone of claim 1 to 3, wherein said human Tr1 cell population is directed against HSP60, HSP70, HSP90 and fragments or mixtures thereof. 
Lijek ili farmaceutski pripravak prema jednom od zahtjeva 1 do 3, naznačeni time da navedena populacija ljudskih Tr1 stanica djeluje protiv HSP60, HSP70, HSP90 i kombinacija istih.
The use according to anyone of claims 5 to 14, wherein the medicament or pharmaceutical composition to be administered to a subject in need thereof comprises human Tr1 cells autologous to the cells of said subject. 
Lijek ili farmaceutski pripravak prema jednom od zahtjeva 5 do 12, naznačeni time da se lijek ili farmaceutski pripravak koji se daje potrebitom subjektu sastoji od Tr1 stanica koje su autologne stanicama tog subjekta.
The formulation according to any of claims 1 to 3 containing the antibody in an amount of at least 120 mg/ml. 
Formulacija prema zahtjevu 3 naznačena time da sadrži protutijelo u količini od barem 120 mg/ml.
The formulation according to any of the preceding claims, which is stable at 22-28°C for at least 6 months. 
Formulacija prema zahtjevu 10 ili 11, naznačena time da je stabilna kod 22-28°C tijekom najmanje 6 mjeseci.
A method for inhibiting dimerization of molecules of an antibody in a liquid formulation containing the antibody, comprising adding arginine and methionine to the liquid formulation. 
Postupak za inhibiciju dimerizacije molekula protutijela u tekućoj formulaciji koja sadrži protutijelo, naznačen time da se sastoji od dodavanja arginina i metionina u tekuću formulaciju.
The blister pack according to Claim 8, in which said top layer (6) comprises at least other two layers (6B, 6C) located on opposite sides of said aluminium layer (6A). 
Blister pakiranje prema 8., naznačeno time da navedeni gornji sloj (6) sadrži najmanje još dva sloja (6B, 6C) koji se nalaze na suprotnim stranama navedenog aluminijskog sloja (6A).
The pharmaceutical preparation for use according to any one of claims 1-3, wherein the ActRIIa-Fc fusion protein is recombinantly expressed in CHO cells using the TPA leader sequence of SEQ ID NO:9. 
Farmaceutska smjesa iz zahtjeva 1 ili 2, naznačena time, što se ActRIIa-Fc fuzijski protein rekombinantno eksprimira u CHO stanicama, uz korištenje TPA liderske sekvence SEQ ID NO: 9.
An integrated device as claimed in claim 1 wherein said wide range of meters comprise specifically customer meters adapted to meter a customer's consumption. 
Integrirani uređaj zahtjevan prema patentnom zahtjevu 1 pri čemu navedeni veliki asortiman brojila obuhvaća izričito brojila korisnika prilagođena za mjerenje korisnikove potrošnje.
An integrated device as claimed in any preceding claim wherein said communication is via SMS (Short Message Service) messaging. 
Integrirani uređaj zahtjevan prema bilo kojem prethodnom patentnom zahtjevu pri čemu je navedena komunikacija putem SMS (usluga kratkih poruka, engl. short message service) razmjene poruka.
An integrated device as claimed in claim 6 wherein said pulse generation means comprise a low frequency pulse transmitter of the type used to convert the rotational movement of a meter's index into electrical pulses at a rate indicative of fluid consumption. 
Integrirani uređaj zahtjevan prema patentnom zahtjevu 6 pri čemu navedena namjena stvaranja impulsa obuhvaća vrstu prijenosnika impulsa niskih frekvencija koji se koristi za pretvorbu kružnog gibanja pokazatelja brojila u električne impulse u omjeru koji naznačuje potrošnju tekućine.
An integrated device as claimed in any preceding claim operable only to communicate pulse readings, without having the functionality to convert said pulse readings to the corresponding amount of fluid consumed. 
Integrirani uređaj zahtjevan prema bilo kojem prethodnom patentnom zahtjevu djelotvoran jedino za prijenos očitanja impulsa, bez mogućnosti pretvorbe navedenih očitanja impulsa u odgovarajuću količinu potrošene tekućine.
An integrated device as claimed in any preceding claim being implemented solely in hardware, without the need for any software for it to function. 
Integrirani uređaj zahtjevan prema bilo kojem prethodnom patentnom zahtjevu koji je ugrađen jedino u opremu, bez potrebe za programom za njegovo funkcioniranje.
An integrated device as claimed in any preceding claim being operable to communicate with a remote meter database such that specific information, for example, the gas supplier, the unique meter reference number, meter model and/or meter calibration, can be identified. 
Integrirani uređaj zahtjevan prema bilo kojem prethodnom patentnom zahtjevu djelotvoran u povezivanju s bazom podataka udaljenog brojila tako da specifična informacija, na primjer, dobavljač plina, jedinstveni identifikacijski broj brojila, model brojila i/ili umjeravanje brojila, može biti prepoznata.